FIRST LINE TREATMENT OF ADVANCED OVARIAN CANCER WITH PACLITAXEL/EPIRUBICIN/CARBOPLATIN (TEC) VS PACLITAXEL/CARBOPLATIN (TC). INTERIM RESULTS OF AN NSGO-EORT-GCG-NCIC-CTG GYNECOLOGICAL CANCER INTERGROUP PHASE III TRIAL

G. Stuart

doi:10.1136/ijgc-00009577-200303001-00020

FIRST LINE TREATMENT OF ADVANCED OVARIAN CANCER WITH PACLITAXEL/EPIRUBICIN/CARBOPLATIN (TEC) VS PACLITAXEL/CARBOPLATIN (TC). INTERIM RESULTS OF AN NSGO-EORT-GCG-NCIC-CTG GYNECOLOGICAL CANCER INTERGROUP PHASE III TRIAL

International Journal of Gynecological Cancer ◽

10.1136/ijgc-00009577-200303001-00020 ◽

2003 ◽

Vol 13 (Suppl 1) ◽

pp. 6.3-7

Author(s):

G. Stuart

Keyword(s):

Ovarian Cancer ◽

Gynecological Cancer ◽

Advanced Ovarian Cancer ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Trial ◽

First Line Treatment

Download Full-text

Paclitaxel/carboplatin (TC) vs. paclitaxel/carboplatin followed by topotecan (TOP) in first-line treatment of advanced ovarian cancer. Mature results of a Gynecologic Cancer Intergroup phase III trial of the AGO OVAR and GINECO

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.lba5007 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. LBA5007-LBA5007 ◽

Cited By ~ 6

Author(s):

J. Pfisterer ◽

B. Weber ◽

A. Du Bois ◽

A. Lortholary ◽

C. Schade-Brittinger ◽

...

Keyword(s):

Ovarian Cancer ◽

Gynecologic Cancer ◽

Advanced Ovarian Cancer ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Trial ◽

First Line Treatment

Download Full-text

Randomized Phase III Trial of Topotecan Following Carboplatin and Paclitaxel in First-line Treatment of Advanced Ovarian Cancer: A Gynecologic Cancer Intergroup Trial of the AGO-OVAR and GINECO

JNCI Journal of the National Cancer Institute ◽

10.1093/jnci/djj296 ◽

2006 ◽

Vol 98 (15) ◽

pp. 1036-1045 ◽

Cited By ~ 141

Author(s):

Jacobus Pfisterer ◽

Béatrice Weber ◽

Alexander Reuss ◽

Rainer Kimmig ◽

Andreas du Bois ◽

...

Keyword(s):

Ovarian Cancer ◽

Gynecologic Cancer ◽

Advanced Ovarian Cancer ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Trial ◽

Intergroup Trial ◽

First Line Treatment

Download Full-text

Randomized Phase III Trial of Topotecan Following Carboplatin and Paclitaxel in First-line Treatment of Advanced Ovarian Cancer: A Gynecologic Cancer Intergroup Trial of the AGO-OVAR and GINECO

Yearbook of Oncology ◽

10.1016/s1040-1741(08)70320-8 ◽

2007 ◽

Vol 2007 ◽

pp. 70-71

Author(s):

J.T. Thigpen

Keyword(s):

Ovarian Cancer ◽

Gynecologic Cancer ◽

Advanced Ovarian Cancer ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Trial ◽

Intergroup Trial ◽

First Line Treatment

Download Full-text

915 POSTER Paclitaxel/carboplatin (TC) versus paclitaxel/carboplatin followed by topotecan (TOP) in first line treatment of advanced ovarian cancer. mature results of a gynecologic cancer interGroup (GCIG) phase III trial of the AGO OVAR and GINECO

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(05)81210-8 ◽

2005 ◽

Vol 3 (2) ◽

pp. 263

Keyword(s):

Ovarian Cancer ◽

Gynecologic Cancer ◽

Advanced Ovarian Cancer ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Trial ◽

First Line Treatment

Download Full-text

Epirubicin/paclitaxel/carboplatin (TEC) vs paclitaxel/carboplatin (TC) in first-line treatment of ovarian cancer (OC) FIGO stages IIB–IV. An AGO-GINECO Intergroup phase III trial

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.5007 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 5007-5007 ◽

Cited By ~ 7

Author(s):

A. du Bois ◽

M. Combe ◽

J. Rochon ◽

C. Jackisch ◽

E. Malaurie ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Trial ◽

First Line Treatment

Download Full-text

Epirubicin/paclitaxel/carboplatin (TEC) vs paclitaxel/carboplatin (TC) in first-line treatment of ovarian cancer FIGO stages IIB-IV. Results of a randomized AGO-GINECO GCIG Intergroup phase III trial

International Journal of Gynecological Cancer ◽

10.1111/j.1525-1438.2005.00439.x ◽

2005 ◽

Vol 15 (s3) ◽

pp. 222-223 ◽

Cited By ~ 2

Author(s):

E. PUJADE-LAURAINE ◽

A. BOIS ◽

A. GOUPIL ◽

J. ROCHON ◽

V. MOBUS ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Trial ◽

First Line Treatment

Download Full-text

Epirubicin/paclitaxel/carboplatin (TEC) vs paclitaxel/carboplatin (TC) in first-line treatment of ovarian cancer (OC) FIGO stages IIB–IV. An AGO-GINECO Intergroup phase III trial

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.5007 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 5007-5007 ◽

Cited By ~ 4

Author(s):

A. du Bois ◽

M. Combe ◽

J. Rochon ◽

C. Jackisch ◽

E. Malaurie ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Trial ◽

First Line Treatment

Download Full-text

36 Paclitaxel/Carboplatin(TC) vs Paclitaxel/Carboplatin sequentially followed by Topotecan (TC-Top) in first-line treatment of ovarian cancer Flgo stages IIB – IV interim results of a gynaecologic cancer intergroup phase III trial of the Ago ovarian cancer study group and Gineco

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(03)90070-x ◽

2003 ◽

Vol 1 (5) ◽

pp. S15 ◽

Cited By ~ 1

Author(s):

E. Pujade-Lauraine ◽

J. Pfisterer ◽

A. Lortholary ◽

R. Kimmig ◽

B. Weber ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Iii ◽

Study Group ◽

Line Treatment ◽

First Line ◽

Phase Iii Trial ◽

Cancer Study ◽

Cancer Study Group ◽

Gynaecologic Cancer ◽

First Line Treatment

Download Full-text

Faculty Opinions recommendation of Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13360090.14731177 ◽

2011 ◽

Author(s):

Joanna Cain

Keyword(s):

Ovarian Cancer ◽

Liposomal Doxorubicin ◽

Pegylated Liposomal Doxorubicin ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Trial ◽

First Line Treatment

Download Full-text

Faculty Opinions recommendation of Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13360090.14730236 ◽

2011 ◽

Author(s):

David Kushner ◽

Shitanshu Uppal

Keyword(s):

Ovarian Cancer ◽

Liposomal Doxorubicin ◽

Pegylated Liposomal Doxorubicin ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Trial ◽

First Line Treatment

Download Full-text